Microbiota Study in Liver Transplanted Patients (BIM-LT)

Biliary and Intestinal Microbiota Study in Liver Transplanted Patients

Many studies describe the relationship between microbiota alteration and the occurrence of metabolic, alcoholic or inflammatory liver diseases. Nevertheless, the modifications of microbiota during liver transplantation (LT) as well as its implication are poorly studied. Similarly, only the intestinal microbiota is studied in this context, and no data are available on the biliary microbiota, even if it is known that bile microbiota can interfere with hepatobiliary diseases.

This study proposes a clinical and biological in-depth follow-up with multiple sampling of liver transplanted patients to study biliary and intestinal microbiota alterations along LT, as well as bile acids metabolism in corresponding fluids.

Indeed, in recipient samples as saliva, blood, urine, and feces can be taken before LT, and surgeons can easily perform bile sampling during LT. In donors all samples can be taken during liver removal. This offers the opportunity to have a microbiotic landscape of individuals without liver disease (donor), and patients suffering from a chronic liver disease or a liver cancer before and after transplantation.

Also, in Grenoble University hospital, in case of biliary anastomotic incongruence, a biliary stent is placed during LT in 60% of recipients. This stent is removed by endoscopic retrograde cholangiopancreatography (ERCP) within 6 months after LT, offering a second opportunity to obtain bile samples in transplanted patients, after the early post-LT period. Patients who do not require a biliary stent will also be included for the study of secondary objectives, as intestinal microbiota is very poorly characterized in liver transplanted patients too. A portion of the patients without biliary stent, may also develop an anastomotic biliary stricture requiring an ERCP. If this ERCP is realized within the follow-up period of the study, the patient will also be included in the primary objective of the study.

These multiple and sequential samples will allow a complete analysis of microbiota changes in LT patients and aim to answer to 3 questions:

1. What are the modifications of intestinal and biliary microbiomes during LT?
2. What is the influence of bile acids' composition on intestinal and biliary microbiota?
3. What are the relationships between microbiome alterations and the emergence of LT complications?

Study Overview

• Status: Unknown
• Conditions: Hepatocellular Carcinoma; Cirrhosis; Microbiota; Liver Transplant
• Intervention / Treatment: Other: Multiple sampling

• Study Type: Observational
• Enrollment (Anticipated): 50

Contacts and Locations

• Study Contact: Name: Gael ROTH, MD; Phone Number: +33 476 766 739; Email: groth@chu-grenoble.fr

Study Locations

• France
  • Grenoble, France, 38100
    • Recruiting
    • CHU de Grenoble Alpes
    • Contact: Gaël ROTH; Email: GRoth@chu-grenoble.fr

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 70 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

• Sampling Method: Non-Probability Sample

Study Population

Patients registered on the waiting list fo liver transplantation

Description

Inclusion Criteria:

Recipients:

• Age ≥ 18 years old
• Absence of LT contraindications
• Patient undergoing liver transplantation
• Patient legally able to give written consent.
• Person affiliated to social security

Donors:

Cadaveric-donor liver transplantation

Exclusion Criteria:

• Living-related liver transplantation
• LT contraindications
• All subjects protected by articles L1121-5 and L1121-8 of French public health law (Subject under administrative or judicial control, person who are protected under the act, person hospitalized without their consent, prisoners and pregnant or breast-feeding women).

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comparison of the relative abundance of pathobionts and symbionts before and 6 months after liver transplantation, in the bile of recipients.	Beneficial bacterias/pathobionts ratio before and 6 months after liver transplantation in the bile of recipients.	During LT and 6 months after LT

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Comparison of the relative abundance of pathobionts and beneficial bacteria at the time, and 6 months after liver transplantation, in the feces of recipients.	Intestinal beneficial bacterias/pathobionts ratio before and 6 months after liver transplantation in recipients.	Before LT (6 months maximum) and 6 months after LT
Comparison of bile microbial diversity at the time, and 6 months after liver transplantation, in LT recipients.	Proportion of the different microbial populations in recipients' bile.	During LT and 6 months after LT
Comparison of fecal microbial diversity before, and 6 months after liver transplantation, in LT recipients.	Proportion of the different microbial populations in recipients' feces.	Before LT (6 months maximum) and 6 months after LT
Study the correlation between bile microbiota of donors and recipients after LT.	Proportion of the different biliary microbial populations of donors and in their corresponding recipient.	During LT and 6 months after LT
Study the correlation between fecal microbiota of donors and recipients after LT.	Proportion of the different intestinal microbial populations of donors and their corresponding recipient.	Before LT (6 months maximum) and 6 months after LT
Study the relationships between bile microbiota changes and intestinal microbiota modifications in recipients, before and after LT.	Correlation between microbial populations' proportions in bile and in feces in donors and in recipients.	Before LT (6 months maximum) and 6 months after LT
Study the modifications of bile acid profiles in recipients between before and after LT.	Proportions of total, primary and secondary biles acids in urine, feces and bile of donors and recipients.	Before LT (6 months maximum) and 6 months after LT
Study the influence of bile acids'composition on bile microbiota along transplantation.	Correlation between the evolution of pathobionts and beneficial bacterias' proportions in bile and the different bile acids (BA) profiles (proportions of primary and secondary BAs).	Before LT (6 months maximum) and 6 months after LT
Study the influence of bile acids' composition on intestinal microbiota along transplantation.	Correlation between the evolution of pathobionts and beneficial bacterias' proportions in feces and the different bile acids profiles (proportions of primary and secondary BAs) before and after LT.	Before LT (6 months maximum) and 6 months after LT
Study the relationships between microbiota and the emergence of LT complications (post LT infections, acute liver allograft reject, etc).	Correlation between the evolution of pathobionts and beneficial bacterias' proportions in feces and the different bile acids profiles (proportions of primary and secondary BAs).	Before LT (6 months maximum) and 6 months after LT
Biobanking of blood, saliva, bile, feces and urine for further analyses such as metabolomic studies on blood, urine and feces metagenomic studies on saliva, and immunomonitoring on blood.		Before LT (6 months maximum) and 6 months after LT

Collaborators and Investigators

• Sponsor: University Hospital, Grenoble
• Investigators: Principal Investigator: Gael ROTH, MD, Grenoble Alpes University Hospital

Study record dates

Study Major Dates

• Study Start (Actual): April 16, 2019
• Primary Completion (Anticipated): November 1, 2021
• Study Completion (Anticipated): May 1, 2022

Study Registration Dates

• First Submitted: April 5, 2018
• First Submitted That Met QC Criteria: April 13, 2018
• First Posted (Actual): April 24, 2018

Study Record Updates

• Last Update Posted (Actual): November 5, 2019
• Last Update Submitted That Met QC Criteria: November 4, 2019
• Last Verified: April 1, 2019

More Information

Terms related to this study

• Keywords: Liver transplantation; Microbiota; hepatocellular carcinoma; cirrhosis
• Additional Relevant MeSH Terms: Digestive System Diseases; Pathologic Processes; Neoplasms by Histologic Type; Neoplasms; Neoplasms by Site; Adenocarcinoma; Carcinoma; Neoplasms, Glandular and Epithelial; Digestive System Neoplasms; Liver Diseases; Liver Neoplasms; Fibrosis; Carcinoma, Hepatocellular
• Other Study ID Numbers: 38RC17.332

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No